Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2- Early Breast Cancer Patients

被引:4
作者
Li, Shuai [1 ]
Chen, Xiaosong [1 ]
Shen, Kunwei [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Dept Gen Surg,Sch Med, Shanghai, Peoples R China
来源
FRONTIERS IN SURGERY | 2022年 / 9卷
基金
中国国家自然科学基金;
关键词
breast neoplasms; core needle biopsy; surgical sample; Ki-67; change; prognosis; INTERNATIONAL EXPERT CONSENSUS; HER2; STATUS; SURGICAL SPECIMENS; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; AMERICAN SOCIETY; KI67; EXPRESSION; WOMEN; INDEX; EXCISION;
D O I
10.3389/fsurg.2022.905575
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background; To investigate the association of Ki-67 change pattern after core needle biopsy (CNB) and prognosis in HR+/HER2- early breast cancer patients. Method: Eligible patients were categorized into three groups: Low group, Elevation group, and High group. Chi-square test and logistic regression analysis were used to compare the clinic-pathological characteristics. Kaplan-Meier method was used to estimate the rates of recurrence-free interval (RFI) and breast cancer-specific survival (BCSS), which were compared via the Log-rank test. Cox proportional hazard analysis was performed to investigate independent prognostic factors. Results: A total of 2,858 patients were included: 1,179 (41.3%), 482 (16.9%), and 1,197 (41.8%) patients were classified into the low, elevation, and high groups, respectively. Age, tumor size, histological grade, lymph-vascular invasion (LVI), and ER level status were associated with Ki-67 change pattern after CNB. With a median follow-up of 53.6 months, the estimated 5-year RFI rates for the low group, elevation, and high groups were 96.4%, 95.3% and 90.9%, respectively (P < 0.001). And 5-year BCSS rates were 99.3%, 98.3% and 96.8%, respectively (P = 0.001). Compared with patients in the low group, patients in the high group had significantly worse RFI (hazard ratio [HR] 1.71, 95% confidence interval [CI] 1.16-2.54) in multivariate analysis. Conclusions: Ki-67 change after CNB was associated with prognosis in HR+/HER2- early breast cancer. Patients with Ki-67 high or elevation after CNB had an inferior disease outcome, indicating the necessity of re-evaluating Ki-67 on surgical specimens after CNB.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER+, and HER2- Breast Cancer
    Yanai, Ayako
    Inoue, Natsuko
    Yagi, Tomoko
    Nishimukai, Arisa
    Miyagawa, Yoshimasa
    Murase, Keiko
    Imamura, Michiko
    Enomoto, Yukie
    Takatsuka, Yuichi
    Watanabe, Takahiro
    Hirota, Seiichi
    Sasa, Mitsunori
    Katagiri, Toyomasa
    Miyoshi, Yasuo
    CLINICAL BREAST CANCER, 2015, 15 (03) : 197 - 203
  • [42] Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients
    Ding, Li
    Zhang, Zijin
    Xu, Yan
    Zhang, Yongqiang
    BIOENGINEERED, 2017, 8 (04) : 383 - 392
  • [43] Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study
    Zong, Yu
    Zhu, Li
    Wu, Jiayi
    Chen, Xiaosong
    Huang, Ou
    Fei, Xiaochun
    He, Jianrong
    Chen, Weiguo
    Li, Yafen
    Shen, Kunwei
    PLOS ONE, 2014, 9 (08):
  • [44] Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature
    Mooghal, Mehwish
    Khan, Muhammad Ali Akbar
    Samar, Mirza Rameez
    Shaikh, Hafsa
    Valimohammad, Azmina Tajdin
    Idrees, Romana
    Rashid, Yasmin Abdul
    Sattar, Abida K.
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2024, 18
  • [45] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
    Perrone, Valentina
    Dovizio, Melania
    Leogrande, Melania
    Tamma, Antonella
    Giovannitti, Massimo
    Buzzoni, Carlotta
    Esposti, Luca Degli
    BREAST CANCER MANAGEMENT, 2023, 12 (02)
  • [46] Correlation between ER, PR, HER-2, and Ki-67 with the risk of bone metastases detected by bone scintigraphy in breast cancer patients: A cross sectional study
    Afkari, Hanif
    Makrufardi, Firdian
    Hidayat, Basuki
    Budiawan, Hendra
    Kartamihardja, Achmad Hussein Sundawa
    ANNALS OF MEDICINE AND SURGERY, 2021, 67
  • [47] HER2-Low Status Is Not Accurate in Breast Cancer Core Needle Biopsy Samples: An Analysis of 5610 Consecutive Patients
    Lu, Yujie
    Zhu, Siji
    Tong, Yiwei
    Fei, Xiaochun
    Jiang, Wu
    Shen, Kunwei
    Chen, Xiaosong
    CANCERS, 2022, 14 (24)
  • [48] De-escalated therapy for HR+/HER2+breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
    Guarneri, V
    Dieci, M., V
    Bisagni, G.
    Frassoldati, A.
    Bianchi, G., V
    De Salvo, G. L.
    Orvieto, E.
    Urso, L.
    Pascual, T.
    Pare, L.
    Galvan, P.
    Ambroggi, M.
    Giorgi, C. A.
    Moretti, G.
    Griguolo, G.
    Vicini, R.
    Prat, A.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2019, 30 (06) : 921 - 926
  • [49] Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
    Synnestvedt, Marit
    Borgen, Elin
    Russnes, Hege G.
    Kumar, Neena T.
    Schlichting, Ellen
    Giercksky, Karl-Erik
    Karesen, Rolf
    Nesland, Jahn M.
    Naume, Bjorn
    ACTA ONCOLOGICA, 2013, 52 (01) : 91 - 101
  • [50] Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
    Engel-Nitz, Nicole M.
    Johnson, Mary G.
    Johnson, Michael P.
    Cha-Silva, Ashley S.
    Kurosky, Samantha K.
    Liu, Xianchen
    PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 1049 - 1062